Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.59 - $1.04 $7,282 - $12,837
-12,344 Reduced 99.48%
64 $0
Q1 2024

May 13, 2024

BUY
$0.61 - $0.83 $4,005 - $5,450
6,567 Added 112.43%
12,408 $8,000
Q4 2023

Feb 09, 2024

BUY
$0.42 - $0.86 $2,426 - $4,968
5,777 Added 9026.56%
5,841 $4,000
Q1 2023

May 12, 2023

SELL
$0.72 - $1.03 $406 - $580
-564 Reduced 89.81%
64 $0
Q4 2022

Feb 08, 2023

BUY
$0.73 - $14.6 $411 - $8,234
564 Added 881.25%
628 $0
Q3 2022

Nov 10, 2022

BUY
$1.27 - $15.0 $10 - $120
8 Added 14.29%
64 $0
Q2 2022

Aug 10, 2022

SELL
$1.33 - $2.31 $2,117 - $3,677
-1,592 Reduced 96.6%
56 $0
Q1 2022

May 16, 2022

SELL
$1.26 - $2.52 $10,313 - $20,626
-8,185 Reduced 83.24%
1,648 $4,000
Q4 2021

Feb 14, 2022

BUY
$2.33 - $5.94 $15,732 - $40,106
6,752 Added 219.15%
9,833 $23,000
Q3 2021

Nov 15, 2021

SELL
$5.89 - $9.35 $7,191 - $11,416
-1,221 Reduced 28.38%
3,081 $18,000
Q2 2021

Aug 13, 2021

BUY
$9.16 - $19.51 $3,572 - $7,608
390 Added 9.97%
4,302 $39,000
Q1 2021

May 12, 2021

BUY
$10.64 - $14.7 $20,279 - $28,018
1,906 Added 95.01%
3,912 $53,000
Q4 2020

Feb 11, 2021

BUY
$9.32 - $13.63 $16,421 - $24,016
1,762 Added 722.13%
2,006 $22,000
Q3 2020

Nov 12, 2020

SELL
$8.59 - $11.89 $34,179 - $47,310
-3,979 Reduced 94.22%
244 $2,000
Q2 2020

Jul 31, 2020

SELL
$7.23 - $12.1 $36,330 - $60,802
-5,025 Reduced 54.34%
4,223 $49,000
Q1 2020

May 01, 2020

SELL
$5.9 - $13.8 $28,202 - $65,964
-4,780 Reduced 34.07%
9,248 $76,000
Q4 2019

Feb 14, 2020

BUY
$6.51 - $12.23 $67,150 - $126,152
10,315 Added 277.81%
14,028 $172,000
Q3 2019

Nov 14, 2019

BUY
$6.45 - $8.44 $11,274 - $14,753
1,748 Added 88.96%
3,713 $28,000
Q2 2019

Aug 14, 2019

BUY
$6.16 - $14.15 $12,104 - $27,804
1,965 New
1,965 $13,000

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $98.7M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.